Skip to main content Accesibility Help
×
×
Home
  • Print publication year: 2012
  • Online publication date: August 2012

5 - Evidence-based pharmacotherapy of panic disorder

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Essential Evidence-Based Psychopharmacology
  • Online ISBN: 9780511910395
  • Book DOI: https://doi.org/10.1017/CBO9780511910395
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

Alonso J, Angermeyer MC, Bernert S et al. (2004). Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatrica Scandinavica 420 (Suppl.), 38–46.
American Psychiatric Association (2009). Practice Guidelines for the Treatment of Patients with Panic Disorder, 2nd edn. Washington, DC: American Psychiatric Association.
Andlin-Sobocki P, Wittchen HU (2005). Cost of anxiety disorders in Europe. European Journal of Neurology 12 (Suppl. 1), 39–44.
Andrews G (2003). Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Australian and New Zealand Journal of Psychiatry 37, 641–656.
Bakker A, van Balkom AJ, Spinhoven P (2002). SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatrica Scandinavica 106, 163–167.
Bakker A, van Balkom AJ, Spinhoven P et al. (1998). Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. Journal of Nervous and Mental Disease 186, 414–419.
Bakker A, van Balkom AJ, Stein DJ (2005). Evidence-based pharmacotherapy of panic disorder. International Journal of Neuropsychopharmacology 8, 473–482.
Bakker A, van Dyck R, Spinhoven P, van Balkom AJ (1999). Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Journal of Clinical Psychiatry 60, 831–838.
Baldwin DS, Anderson IM, Nutt DJ et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 19, 567–596.
Ballenger JC (1991). Long-term pharmacologic treatment of panic disorder. Journal of Clinical Psychiatry 52 (Suppl.), 18–23.
Ballenger JC (2000). Panic disorder and agoraphobia. In Gelder MG, Lopez-lbor JJ, Andreasen NC (Eds.), New Oxford Textbook of Psychiatry (pp. 807–822). Oxford: Oxford University Press.
Bandelow B, Zohar J, Hollander E et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World Journal of Biological Psychiatry 9, 248–312.
Batelaan N, Smit F, de Graaf R et al. (2007). Economic costs of full-blown and subthreshold panic disorder. Journal of Affective Disorders 104, 127–136.
Batelaan NM, de Graaf R, Penninx BW et al. (2010a). The 2-year prognosis of panic episodes in the general population. Psychological Medicine 40, 147–157.
Batelaan NM, de Graaf R, Spijker J et al. (2010 b). The course of panic attacks in individuals with panic disorder and subthreshold panic disorder: a population-based study. Journal of Affective Disorders 121, 30–38.
Bertani A, Perna G, Migliarese G et al. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37, 206–210.
Blaya C, Seganfredo AC, Dornelles M et al. (2007). The efficacy of milnacipran in panic disorder: an open trial. International Clinical Psychopharmacology 22, 153–158.
Bradwejn J, Ahokas A, Stein DJ et al. (2005). Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. British Journal of Psychiatry 187, 352–359.
Broocks A, Bandelow B, Pekrun G et al. (1998). Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. American Journal of Psychiatry 155, 603–609.
Bruce SE, Vasile RG, Goisman RM et al. (2003). Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? American Journal of Psychiatry 160, 1432–1438.
Bruce TJ, Spiegel DA, Hegel MT (1999). Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. Journal of Consulting and Clinical Psychology 67, 151–156.
Burrows GD, Judd FK, Norman TR (1993). Long-term drug treatment of panic disorder. Journal of Psychiatric Research 27 (Suppl. 1), 111–125.
Burrows GD, Norman TR (1999). The treatment of panic disorder with benzodiazepines. In Nutt DJ, Ballenger JC, Lepine JP (Eds.), Panic Disorder: Clinical Diagnosis, Management and Mechanisms (pp. 145–158). London: Martin Dunitz.
Canadian Psychiatric Association (2006). Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 51 (Suppl.), 9–91.
Chen YH, Tsai SY, Lee HC, Lin HC (2009). Increased risk of acute myocardial infarction for patients with panic disorder: a nationwide population-based study. Psychosomatic Medicine 71, 798–804.
Choy Y, Peselow ED, Case BG et al. (2007). Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Comprehensive Psychiatry 48, 419–425.
Coryell W, Noyes R, Clancy J (1982). Excess mortality in panic disorder. A comparison with primary unipolar depression. Archives of General Psychiatry 39, 701–703.
Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N (2009). Anxiety disorders and suicidality in the National Comorbidity Survey – Replication. Journal of Psychiatric Research 43, 825–829.
Cross National Collaborative Panic Study (1992). Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. British Journal of Psychiatry 160, 191–202.
Curtis GC, Massana J, Udina C et al. (1993). Maintenance drug therapy of panic disorder. Journal of Psychiatric Research 27 (Suppl. 1), 127–142.
Dannon PN, lancu I, Grunhaus L (2002). The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Human Psychopharmacology 17, 329–333.
Dannon PN, lancu I, Lowengrub K et al. (2007). A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clinical Neuropharmacology 30, 326–334.
de Graaf R, Bijl RV, Spijker J et al. (2003). Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders – findings from the Netherlands Mental Health Survey and Incidence Study. Social Psychiatry and Psychiatric Epidemiology 38, 1–11.
Donovan MR, Glue P, Kolluri S, Emir B (2010). Comparative efficacy of antidepressants in preventing relapse in anxiety disorders – a meta-analysis. Journal of Affective Disorders 123, 9–16.
Eaton WW, Anthony JC, Romanoski A et al. (1998). Onset and recovery from panic disorder in the Baltimore Epidemiologic Catchment Area follow-up. British Journal of Psychiatry 173, 501–507.
Esquivel, G, Az-Galvis J, Schruers K et al. (2008). Acute exercise reduces the effects of a 35% CO2 challenge in patients with panic disorder. Journal of Affective Disorders 107, 217–220.
Fava GA, Mangelli L (1999). Subclinical symptoms of panic disorder: new insights into pathophysiology and treatment. Psychotherapy and Psychosomatics 68, 281–289.
Fava GA, Rafanelli C, Grandi S et al. (2001). Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychological Medicine 31, 891–898.
Ferguson JM, Khan A, Mangano R et al. (2007). Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. Journal of Clinical Psychiatry 68, 58–68.
Furukawa TA, Watanabe N, Churchill R (2007). Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews 1, CD004364.
Goddard AW, Brouette T, Almai A et al. (2001). Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry 58, 681–686.
Gomez-Caminero A, Blumentals WA, Russo LJ et al. (2005). Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database. Psychosomatic Medicine 67, 688–691.
Goodwin RD, Faravelli C, Rosi S et al. (2005). The epidemiology of panic disorder and agoraphobia in Europe. European Neuropsychopharmacology 15, 435–443.
Goodwin RD, Roy-Byrne P (2006). Panic and suicidal ideation and suicide attempts: results from the National Comorbidity Survey. Depression and Anxiety 23, 124–132.
Grasbeck A, Rorsman B, Hagne NO, Isberg PE (1996). Mortality of anxiety syndromes in a normal population. The Lundby Study. Neuropsychobiology 33, 118–126.
Harvison KW, Woodruff-Borden J, Jeffery SE (2004). Mismanagement of panic disorder in emergency departments: contributors, costs, and implications for integrated models of care. Journal of Clinical Psychology and Medicine 11, 217–232.
Hirschfeld RM (1996). Panic disorder: diagnosis, epidemiology, and clinical course. Journal of Clinical Psychiatry 57 (Suppl. 10), 3–8.
Hoehn-Saric R, McLeod DR, Hipsley PA (1993). Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmacology 13, 321–326.
Hofmann SG (2007). Enhancing exposure-based therapy from a translational research perspective. Behaviour Research and Therapy 45, 1987–2001.
Hoge EA, Worthington JJ 3rd, Kaufman RE et al. (2008). Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectrums 13, 522–527.
Holland Rl, Fawcett J, Hoehn-Saric R (1994). Long-term treatment of panic disorder with fluvoxamine in out-patients who had completed double-blind trials. Neuropsychopharmacology 10 (Suppl. 3), 102.
Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH (2005). Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety 21, 33–40.
Hornig CD, McNally RJ (1995). Panic disorder and suicide attempt. A reanalysis of data from the Epidemiologic Catchment Area study. British Journal of Psychiatry 167, 76–79.
Ipser JC, Carey P, Dhansay Y et al. (2006). Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database of Systematic Reviews 4, CD005473.
Johnson J, Weissman MM, Klerman GL (1990). Panic disorder, comorbidity, and suicide attempts. Archives of General Psychiatry 47, 805–808.
Katerndahl DA, Realini JP (1995). Where do panic attack sufferers seek care? Journal of Family Practice 40, 237–243.
Katerndahl DA, Realini JP (1997). Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder. Journal of Clinical Psychiatry 58, 153–158.
Kessler RC, Chiu WT, Jin R et al. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 63, 415–424.
Kessler RC, Stang PE, Wittchen HU et al. (1998). Lifetime panic-depression comorbidity in the National Comorbidity Survey. Archives of General Psychiatry 55, 801–808.
Kjernisted K, Mclntosh D (2007). Venlafaxine extended release (XR) in the treatment of panic disorder. Therapeutics and Clinical Risk Management 3, 59–69.
Klerman GL, Weissman MM, Ouellette R et al. (1991). Panic attacks in the community. Social morbidity and health care utilization. Journal of the American Medical Association 265, 742–746.
Kohn R, Saxena S, Levav I, Saraceno B (2004). The treatment gap in mental health care. Bulletin of the World Health Organization 82, 858–866.
Kouzis AC, Eaton WW (1994). Emotional disability days: prevalence and predictors. American Journal of Public Health 84, 1304–1307.
Kouzis AC, Eaton WW (1997). Psychopathology and the development of disability. Social Psychiatry and Psychiatric Epidemiology 32, 379–386.
Kruger MB, Dahl AA (1999). The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. European Archives of Psychiatry and Clinical Neuroscience 249, S19–S24.
Kuijpers PM, Honig A, Griez EJ et al. (2000). [Panic disorder in patients with chest pain and palpitations: an often unrecognized relationship]. Nederlands Tijdschrift voor Geneeskunde 144, 732–736.
Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ (2009). Angststoornissen: Paniekstoornis en PTSS (eerste revisie). Utrecht: Trimbos-instituut.
Lecrubier Y, Bakker A, Dunbar G, Judge R (1997). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scandinavica 95, 145–152.
Lecrubier Y, Judge R (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scandinavica 95, 153–160.
Leon AC, Portera L, Weissman MM (1995). The social costs of anxiety disorders. British Journal of Psychiatry 27 (Suppl.), 19–22.
Lepine JP, Chignon JM, Teherani M (1993). Suicide attempts in patients with panic disorder. Archives of General Psychiatry 50, 144–149.
Lepola UM, Wade AG, Leinonen EV et al. (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry 59, 528–534.
Liebowitz MR, Asnis G, Mangano R, Tzanis E (2009). A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. Journal of Clinical Psychiatry 70, 550–561.
Loerch B, Graf-Morgenstern M, Hautzinger M et al. (1999). Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. British Journal of Psychiatry 174, 205–212.
Lotufo-Neto F, Bernik M, Ramos RT et al. (2001). A dose-finding and discontinuation study of clomipramine in panic disorder. Journal of Psychopharmacology 15, 13–17.
Marks IM, Swinson RP, Basoglu M et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. British Journal of Psychiatry 162, 776–787.
Mavissakalian M, Perel JM (1992). Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry 49, 318–323.
Mavissakalian MR, Perel JM (1995). Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. American Journal of Psychiatry 152, 673–682.
Mavissakalian MR, Perel JM (1999). Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry 56, 821–827.
Mavissakalian MR, Perel JM (2002). Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology 22, 294–299.
Michelson D, Lydiard RB, Pollack MH et al. (1998). Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. American Journal of Psychiatry 155, 1570–1577.
Mula M, Pini S, Cassano GB (2007). The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. Journal of Clinical Psychopharmacology 27, 263–272.
Noyes R Jr, Garvey MJ, Cook B, Suelzer M (1991). Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry 148, 517–523.
Noyes R Jr, Garvey MJ, Cook BL, Samuelson L (1989). Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. Journal of Clinical Psychiatry 50, 163–169.
Oei TPS, Llamas M, Devilly GJ (1999). The efficacy and cognitive processes of cognitive behaviour therapy in the treatment of panic disorder with agoraphobia. Behavioural and Cognitive Psychotherapy 27, 63–88.
Otto MW, Tolin DF, Simon NM et al. (2010). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry 67, 365–370.
Otto MW, Tuby KS, Gould RA et al. (2001). An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry 158, 1989–1992.
Pande AC, Pollack MH, Crockatt J et al. (2000). Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology 20, 467–471.
Papp LA (2006). Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. Journal of Clinical Psychiatry 67, 1573–1576.
Papp LA, Schneier FR, Fyer AJ et al. (1997). Clomipramine treatment of panic disorder: pros and cons. Journal of Clinical Psychiatry 58, 423–425.
Peter H, Bruckner E, Hand I et al. (2008). Treatment outcome of female agoraphobics 3–9 years after exposure in vivo: a comparison with healthy controls. Journal of Behaviour Therapy and Experimental Psychiatry 39, 3–10.
Pigot M, Loo C, Sachdev P (2008). Repetitive transcranial magnetic stimulation as treatment for anxiety disorders. Expert Review of Neurotherapeutics 8, 1449–1455.
Pollack M, Mangano R, Entsuah R et al. (2007 a). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194, 233–242.
Pollack MH, Lepola U, Koponen H et al. (2007 b). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety 24, 1–14.
Pollack MH, Otto MW, Worthington JJ et al. (1998). Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Archives of General Psychiatry 55, 1010–1016.
Pollack MH, Simon NM, Worthington JJ et al. (2003). Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. Journal of Psychopharmacology 17, 276–282.
Pollack MH, Tesar GE, Rosenbaum JF, Spier SA (1986). Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. Journal of Clinical Psychopharmacology 6, 302–304.
Rapaport MH, Wolkow R, Rubin A et al. (2001). Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatrica Scandinavica 104, 289–298.
Ravelli A, Bijl RV, van Zessen G (1998). Comorbiditeit van psychiatrische stoornissen in de Nederlandse bevolking: Resultaten van de Netherlands Mental Health Survey and Incidence Study (NEMESIS). Tijdschrift voor Psychiatrie 40, 531–544.
Rees CS, Richards JC, Smith LM (1998). Medical utilisation and costs in panic disorder: a comparison with social phobia. Journal of Anxiety Disorders 12, 421–435.
Rodrigues H, Figueira I, Goncalves R et al. (2011). CBT for pharmacotherapy non-remitters – a systematic review of a next-step strategy. Journal of Affective Disorders 129, 219–228.
Rosenberg R (1999). Treatment of panic disorder with tricyclics and MAOIs. In Nutt DJ, Ballenger JC, Lépine PD (Eds.), Panic Disorder: Clinical Diagnosis, Management and Mechanisms (pp. 125–144) London: Martin Dunitz.
Ross DC, Klein DF, Uhlenhuth EH (2010). Improved statistical analysis of moclobemide dose effects on panic disorder treatment. European Archives of Psychiatry and Clinical Neuroscience 260, 243–248.
Ruhe HG, Booij J, Weert HC et al. (2009). Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 34, 999–1010.
Saito M, Miyaoka H (2007). Augmentation of paroxetine with clocapramine in panic disorder. Psychiatry and Clinical Neurosciences 61, 449.
Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J (1995). Costs and offset effect in panic disorders. British Journal of Psychiatry 27 (Suppl.), 23–28.
Sareen J, Cox BJ, Afifi TO et al. (2005a). Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Archives of General Psychiatry 62, 1249–1257.
Sareen J, Cox BJ, Clara I, Asmundson GJ (2005 b). The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depression and Anxiety 21, 193–202.
Schmidt NB, Wollaway-Bickel K, Trakowski JH et al. (2002). Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behaviour Research and Therapy 40, 67–73.
Seedat S, van Rheede van Oudtshoorn E, Muller JE et al. (2003). Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. International Clinical Psychopharmacology 18, 279–284.
Sepede G, de Berardis D, Gambi F et al. (2006). Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology 26, 45–49.
Sheehan DV, Ballenger J, Jacobsen G (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry 37, 51–59.
Sheehan DV, Burnham DB, lyengar MK, Perera P (2005). Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Journal of Clinical Psychiatry 66, 34–40.
Simon NM, Hoge EA, Fischmann D et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. Journal of Clinical Psychiatry 67, 381–385.
Simon NM, Kaufman RE, Hoge EA et al. (2009 a). Open-label support for duloxetine for the treatment of panic disorder. CNS Neuroscience and Therapeutics 15, 19–23.
Simon NM, Otto MW, Worthington JJ et al. (2009 b). Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Journal of Clinical Psychiatry 70, 1563–1570.
Smoller JW, Pollack MH, Wassertheil-Smoller S et al. (2007). Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Archives of General Psychiatry 64, 1153–1160.
Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A (1994). Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? American Journal of Psychiatry 151, 876–881.
Stahl SM, Gergel I, Li D (2003). Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 64, 1322–1327.
Stein MB, Cantrell CR, Sokol MC et al. (2006). Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric Services 57, 673–680.
Strohle A, Graetz B, Scheel M et al. (2009). The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. Journal of Psychiatric Research 43, 1013–1017.
Tiller JW, Bouwer C, Behnke K (1999). Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. European Archives of Psychiatry and Clinical Neuroscience 249, S7–S10.
Toni C, Perugi G, Frare F et al. (2004). Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatrica Scandinavica 110, 130–137.
Tyrer P, Candy J, Kelly D (1973). A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32, 237–254.
Uhlenhuth EH, Warner TD, Matuzas W (2002). Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. Journal of Clinical Psychopharmacology 174, 205–212.
Van Balkom AJ, Bakker A, Spinhoven P et al. (1997). A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. Journal of Nervous and Mental Disease 185, 510–516.
Van Balkom AJLM, Nauta M, Bakker A (1995). Meta-analysis on the treatment of panic disorder with agoraphobia: review and re-examination. Clinical Psychology and Psychotherapy 2, 1–14.
Versiani M, Cassano G, Benedetti A et al. (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Journal of Clinical Psychiatry 63, 31–37.
Wade AG, Lepola U, Koponen HJ et al. (1997). The effect of citalopram in panic disorder. British Journal of Psychiatry 170, 549–553.
Wang PS, Berglund P, Olfson M et al. (2005 a). Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 603–613.
Wang PS, Lane M, Olfson M et al. (2005 b). Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Archives of General Psychiatry 62, 629–640.
Watanabe N, Churchill R, Furukawa TA (2007). Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry 7, 18.
Wedekind D, Broocks A, Weiss N et al. (2010). A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World Journal of Biological Psychiatry 11, 904–913.
Weissman MM, Klerman GL, Markowitz JS, Ouellette R (1989). Suicidal ideation and suicide attempts in panic disorder and attacks. New England Journal of Medicine 321, 1209–1214.
Whittal ML, Otto MW, Hong JJ (2001). Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. Behaviour Research and Therapy 39, 939–945.
Wiborg IM, Dahl AA (1996). Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Archives of General Psychiatry 53, 689–694.
Wittchen HU, Beesdo K, Bittner A, Goodwin RD (2003). Depressive episodes – evidence for a causal role of primary anxiety disorders? European Psychiatry 18, 384–393.
Wittchen HU, Nelson CB, Lachner G (1998). Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychological Medicine 28, 109–126.
Wittchen HU, Nocon A, Beesdo K et al. (2008). Agoraphobia and panic. Prospective-longitudinal relations suggest a rethinking of diagnostic concepts. Psychotherapy and Psychosomatics 77, 147–157.
Wright J, Clum GA, Roodman A, Febbraro GA (2000). A bibliotherapy approach to relapse prevention in individuals with panic attacks. Journal of Anxiety Disorders 14, 483–499.
Zwanzger P, Eser D, Nothdurfter C et al. (2009 a). Effects of the GABA-reuptake inhibitor Tiagabine on panic and anxiety in patients with panic disorder. Pharmapsychiatry 42, 266–269.
Zwanzger P, Fallgatter AJ, Zavorotnyy M, Padberg F (2009 b). Anxiolytic effects of transcranial magnetic stimulation – an alternative treatment option in anxiety disorders? Journal of Neural Transmission 116, 767–775.
Zwanzger P, Rupprecht R (2005). Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. Journal of Psychiatry and Neuroscience 30, 167–175.